|
The National Academy of Burns organized the NABICON 2024 at Ranchi was held from February 15 to 17 to explore the recent advances in all aspects of burn prevention, burn wound management, burn reconstruction, rehabilitation and research.
NexoBird from MediWound is now available in India. This was under a collaboration with BSV (Bharat Serums and Vaccines) who has exclusive right to market and distribute NexoBrid in India. With the use of NexoBrid, the results are equivalent to surgeries, without undergoing surgery.
Some of the key topics covered in the conference included training in burn management, advances in keratinocyte delivery in wounds, post burn deformities correction, setting up of an ideal burn unit and awareness in burns, and many more. The conference was organized under the leadership of Dr Anant Sinha, president, NABI & organizing secretary, NABICON 2024.
Alok Khettry, COO- India Business, BSV, said, “Despite the daunting toll burns take globally, there is a light at the end of the tunnel. Burn survivors are often stigmatized with scras (dead tissues) and other deformities that remain a life-long emotional and physical challenge. However, with scientific advancements in burn treatments, burns survivors can now be hopeful of overcoming these challenges without any intrusive surgeries.”
Prof Lior Rosenberg, chief medical officer director, MediWound, “Burn management is based on the three tenets of patient care: No death, no suffering and no scras (dead tissues). NexoBrid is a new paradigm in severe burn wound management. It is a concentrate of proteolytic enzymes enriched in bromelain and is a topically administered biological product that enzymatically removes nonviable burnt tissue, or eschar in patients with deep partial and full-thickness thermal burns within four hours after application without harming the viable tissues.
NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns within four hours of application without harming viable tissue. It is approved in 41 countries in the European Union and other international markets and is at registration-stage with the Food and Drug Administration (FDA). It has been designated as an orphan biologic drug in the US and EU besides other international markets. Vericel holds an exclusive license for North American commercial rights to NexoBrid. Recently, Mediwound have received EMA approval for pediatrics indication extension for NexoBrid.
EscharEx is our next-generation bioactive topical therapeutic under development in the US for debridement of chronic and hard to heal wounds. MW005 is also our topical biological drug for the treatment of non-melanoma skin cancers, is a clinical-stage product candidate under development, said Prof Rosenberg.
|